Dergiler / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 3

The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure

Sayfa
184–190
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

They may be used as diagnostic biomarkers in systolic HF, but the incremental value of measuring UCN1 and ADM in patients tested for pro-BNP is questionable.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Urocortin 1 (UCN1) has vasodilator, diuretic, and natriuretic effects, and its expression increases in heart failure (HF).
📊
Temel Bulgular & Veri:Adrenomedullin (ADM) increases cardiac output and lowers blood pressure in healthy men and in patients with heart failure.
💡
Sonuç & Katkı:They may be used as diagnostic biomarkers in systolic HF, but the incremental value of measuring UCN1 and ADM in patients tested for pro-BNP is questionable.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Urocortin 1 (UCN1) has vasodilator, diuretic, and natriuretic effects, and its expression increases in heart failure (HF). Adrenomedullin (ADM) increases cardiac output and lowers blood pressure in healthy men and in patients with heart failure. The aim of the study was to determine UCN1 and ADM levels in patients with HF, to evaluate the relationship of UCN1 and ADM with various clinical parameters, and to assess UCN1 and ADM as diagnostic markers in HF, in comparison with pro-brain natriuretic peptide (pro-BNP).Methods: We investigated serum levels of UCN1, ADM, and pro-BNP in 86 consecutive patients with systolic HF [ejection fraction (EF) <=45%] and 85 healthy controls. Serum UCN1, ADM, and pro-BNP levels were measured with the ELISA method. Transthoracic echocardiography was performed to determine left ventricular EF and pulmonary artery systolic pressure.Results: UCN1 and ADM levels were higher in HF patients (446.2±145.7 pg/mL, p<0.001; 87.9±4.2 pg/mL, p<0.001 respectively). UCN1 was positively correlated with pro-BNP (r=0.963, p<0.001), ADM (r=0.915, p<0.001), and NYHA (r=0.879, p<0.001); ADM was positively correlated with pro-BNP (r=0.956, p<0.001) and NYHA (r=0.944, p<0.001). Receiver operating characteristic curves yielded an area under the curve of 1.00 (p<0.001) for UCN1, 1.00 (p<0.001) for ADM, and 0.99 (p<0.001) for pro-BNP in the diagnosis of HF.Conclusion: UCN1 and ADM increase with worsening HF and left ventricular dysfunction. They may be used as diagnostic biomarkers in systolic HF, but the incremental value of measuring UCN1 and ADM in patients tested for pro-BNP is questionable.

🔖

Bu Makaleye Atıf Yap

YILDIRIM, E., CENGİZ, M., YILDIRIM, N., ASLAN, K., İPEK, E., KORKMAZ, A. F., ULUSOY, F. R., HATEM, E. (2017). The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 3, 184–190. https://ajindex.com/articles/365844

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19: 9-16
  2. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92
  3. Scarabelli T, Knight R. Urocortins: take them to heart. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 335-42
  4. Seres J, Bornstein SR, Seres P, Willenberg HS, Schulte KM, Scherbaum WA, et al. Corticotropin-releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 2004; 89: 965-70
  5. Bamberger CM, Wald M, Bamberger AM, Ergün S, Beil FU, Schulte HM. Human lymphocytes produce urocortin, but not corticotropinreleasing hormone. J Clin Endocrinol Metab 1998; 83: 708-11
  6. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, et al. Expression of urocortin and corticotropin releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002; 87: 340-6
  7. Kageyama K, Teui K, Tamasawa N, Suda T. Regulation and roles of urocortins in the vascular system. Int J Endocrinol 2012; 12: 1-6
  8. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI, et al. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 2001; 86: 4344-52
  9. Petraglia F, Florio P, Gallo R, Simoncini T, Saviozzi M, Di Blasio AM, et al. Human placenta and fetal membranes express human urocortin mRNA and peptide. J Clin Endocrinol Metab 1996; 81: 3807-10
  10. Fekete EM, Zorrilla EP. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 2007; 28: 1-27
  11. Holmberg BJ, Morrison CD, Keisler DH. Endocrine responses of ovariectomized ewes to i.c.v. infusion of urocortin. J Endocrinol 2001; 171: 517-24
  12. Ikeda K, Tojo K, Sato S, Ebisawa T, Tokudome G, Hosoya T, et al. Urocortin, a newly identified corticotropin-releasing factor related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 1998; 250: 298-304
  13. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997; 272: 115-22
  14. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatr